Jeffrey CPA - Imunon Executive CFO
| IMNN Stock | USD 0.81 0.12 17.39% |
CFO
Jeffrey CPA is Executive CFO of Imunon Inc
| Age | 67 |
| Address | 997 Lenox Drive, Lawrenceville, NJ, United States, 08648 |
| Phone | 609 896 9100 |
| Web | https://imunon.com |
Imunon Management Efficiency
The company has return on total asset (ROA) of (0.6708) % which means that it has lost $0.6708 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4812) %, meaning that it created substantial loss on money invested by shareholders. Imunon's management efficiency ratios could be used to measure how well Imunon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to drop to -0.93. In addition to that, Return On Capital Employed is likely to grow to -1.38. At this time, Imunon's Total Assets are very stable compared to the past year. As of the 24th of November 2024, Other Current Assets is likely to grow to about 2.7 M, while Non Current Assets Total are likely to drop about 3.5 M.Similar Executives
| Found 6 records | CFO Age | ||
| Jiyoung Hwang | Exicure | 47 | |
| Christopher CPA | Avalo Therapeutics | 40 | |
| Yvonne MBA | Senti Biosciences | 64 | |
| Jennifer CPA | Cingulate | 53 | |
| Michael King | SAB Biotherapeutics | 63 | |
| Scott CPA | DiaMedica Therapeutics | 59 | |
Management Performance
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.67 |
Imunon Inc Leadership Team
Elected by the shareholders, the Imunon's board of directors comprises two types of representatives: Imunon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imunon. The board's role is to monitor Imunon's management team and ensure that shareholders' interests are well served. Imunon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imunon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Exec CFO | ||
| Nicholas MD, Ex Officer | ||
| Stacy Lindborg, CEO President | ||
| Susan Eylward, General Secretary | ||
| PharmD MBA, President CEO | ||
| David Gaiero, Chief Officer | ||
| Sebastien MD, Executive Officer | ||
| Timothy CPA, Chief Controller | ||
| David CPA, CFO Secretary | ||
| Jeffrey CPA, Executive CFO | ||
| Michael Tardugno, Executive Chairman | ||
| Marianne Lambertson, Vice Relations | ||
| Khursheed MBA, Executive Officer |
Imunon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imunon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 2.73 M | ||||
| Shares Outstanding | 14.5 M | ||||
| Shares Owned By Insiders | 1.09 % | ||||
| Shares Owned By Institutions | 15.44 % | ||||
| Number Of Shares Shorted | 485.69 K | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 17.94 X | ||||
| Revenue | 125 K |
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
| 0.64 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.85 | VALN | Valneva SE ADR | PairCorr |
| 0.81 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Imunon Stock
| 0.59 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.52 | RNXT | RenovoRx | PairCorr |
| 0.43 | KZR | Kezar Life Sciences | PairCorr |
| 0.39 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.